With Global Horizon, Chinese Angle strategy, BOCG strives to support true innovation and disruptive technology of life science.
Accumulated 100+ years’ experience and US$ 1+ billion proven record, the BOCG veteran team builds its office and franchise in Shenzhen, Shanghai, Hong Kong, and Gothenburg of Sweden, and extensive networks and footprint in Greater China, Asia, USA and Europe.
A signatory to the UN PRI and committed to promoting sustainable development and impact investment.
HONG KONG, January 9, 2026 – Ribo LifeScience Co., Ltd. (“Ribo LifeScience” or the “Company,” Stock Code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics and a multi-round investments portfolio company of Blue Ocean Capital Group (“BOCG”), has officially listed on the Main Board of the Hong Kong Stock Exchange. The Company successfully raised approximately HK$1.83 billion (after exercising the offer size adjustment option), marking the second-largest IPO in the 18A biotech sector since 2022 and the first IPO for Blue Ocean Capital in 2026.
SHENZHEN, December 2025 – During the Fifth Frontiers of Brain Science and Industry Conference and the 2025 Shenzhen Brain-Computer Interface Expo, Blue Ocean Capital officially announced the establishment of its RMB 160 million (US$23 million) Brain Science Seed Fund. This specialized fund is designed to accelerate the transformation of breakthrough research into market-ready solutions, focusing on the most promising frontiers of life science technologies.
Recently, Boan Biotech, a portfolio company of Blue Ocean Capital, announced that its independently developed Boyouping® (Dulaglutide Injection) has been granted marketing approval by the National Medical Products Administration for blood glucose control in adult patients with type 2 diabetes. Boyouping is the world’s first approved dulaglutide biosimilar, showcasing Boan Biotech’s strong R&D capabilities. Congratulations to Boan Biotech!
